查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363191

卵巢癌治疗的市场规模、份额和趋势分析报告：按治疗层级、治疗、最终用途、地区和细分市场预测，2023-2030

Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), By Treatment, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 94 Pages | 商品交期: 2-10个工作天内

价格

卵巢癌药物市场成长与趋势：

Grand View Research, Inc.的最新报告显示，预计2030年全球卵巢癌药物市场规模将达到56.5亿美元，2023年至2030年年复合成长率为6.6%。

该市场的成长主要是由新药采用的增加和强大的管道的存在等要素所推动的。由于老年人口增加和不健康的生活方式，卵巢癌罹患率上升正在推动市场发展。

卵巢癌占女性所有恶性的3.0%，占女性癌症死亡人数的6.0%。 2016 年，卵巢癌在全球造成 235,200新患者和 140,000 例死亡，其中北美和欧洲的发生率最高。

二线和三线非铂类PARP和VEGF抑制剂的引入极大地改变了卵巢癌的治疗策略。据估计，几种生物製药和小分子疗法，包括正在开发的抗体药物复合体(ADC)，将对卵巢癌的治疗谱产生重大影响。

卵巢癌治疗药物市场报告亮点

  • 以治疗方法计算，医院药局板块2022年销售份额最大，为45.37%。政府对癌症研究和治疗的配合措施和资助的增加促进了药物的开发和可近性，医院现在可以提供有效的卵巢癌治疗。按用途，商业细分市场占据最大销售份额，2022 年将达到 88.0%。这是由于对仿製药的需求增加，而慢性病的高负担也促进了成长。
  • 例如，据澳洲联邦称，2020 年，澳洲政府拨款 1,620 万美元用于八个专注于对抗卵巢癌的研究计画。在澳洲和全球整体内，卵巢癌一直是所有女性癌症中存活率最低的。平均而言，每 100 名被诊断出患有卵巢癌的女性中，有 43 人在诊断后 5 年内仍存活。
  • 线上药局部门预计在预测期内将以 8.1% 的最快年复合成长率成长。便利性，特别是对于健康状况不佳的患者而言，正在推动卵巢癌药物市场中在线药房的发展，因为在线药房方便订购卵巢癌药物并将其直接运送到患者家中，这是促进因素。这种可近性消除了获取基本药物的障碍，提高了患者对治疗方法的依从性，并扩大了这些药物的市场范围。
  • 例如，AdooQ BioScience 为客户提供了一个方便的平台来订购卵巢癌药物，特别是 rucaparib。在该网页上，客户可以取得药品名称、描述、剂型、价格等详细资讯。
  • 北美卵巢癌的高发生率是该地区卵巢癌药物市场的关键促进因素，因为它导致对有效治疗方法的巨大且持续的需求，从而导致药物研究和众多我们推动创新以满足患者的需求我们的患者群体。
  • 例如，美国癌症协会的 2023 年美国卵巢癌预测预测，大约有 19,710 名女性将新诊断出患有卵巢癌，大约 13,270 名女性将死于卵巢癌。我是。
  • 亚太地区参与临床试验的人数不断增加，这不仅为卵巢癌患者提供了最治疗方法，而且还通过吸引製药公司和研究人员来到该地区来加速药物开发。卵巢癌治疗药物市场的年复合成长率预计在预测期内最快，为 8.0%。 *。
  • 例如，根据Clinical Trials Arena的数据，从2017年到2022年，亚太地区的临床试验增加了约10%，这一增幅令人印象深刻，超过了美国和欧洲等其他主要地区的成长率。该地区这一增速明显高于同期5.3%的年平均成长率。

目录

第1章调查方法和范围

第2章执行摘要

第3章卵巢癌治疗药物市场变数、趋势与范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 卵巢癌治疗药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章卵巢癌治疗药物：按治疗层级的估计和趋势分析

  • 卵巢癌药物市场：重点
  • 卵巢癌治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • PARP抑制剂
  • 血管新生抑制剂
  • PD-L1抑制剂

第5章卵巢癌治疗：按最终用途分类的估计和趋势分析

  • 卵巢癌药物市场：重点
  • 卵巢癌治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 医院药房
  • 零售药房
  • 网路药房

第6章卵巢癌治疗：治疗的估计和趋势分析

  • 卵巢癌药物市场：重点
  • 卵巢癌治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 化疗
  • 放射治疗
  • 荷尔蒙治疗
  • 标靶治疗等

第7章卵巢癌治疗药物市场：区域估计与趋势分析

  • 区域展望
  • 按地区分類的卵巢癌药物市场：重点
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第8章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • AbbVie Inc.
    • Pfizer, Inc.,
    • AstraZeneca,
    • F. Hoffmann-La Roche AG,
    • Johnson & Johnson Services, Inc.,
    • Boehringer Ingelheim International GmbH,
    • Clovis Oncology,
    • ImmunoGen, Inc.
    • Vivesto AB
Product Code: GVR-2-68038-380-5

Ovarian Cancer Drugs Market Growth & Trends:

The global ovarian cancer drugs market size is expected to reach USD 5.65 billion by 2030, registering a CAGR of 6.6% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.

Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.

Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.

Ovarian Cancer Drugs Market Report Highlights:

  • Based on treatment, the hospital pharmacy segment held the largest revenue share of 45.37% in 2022. An increasing number of government initiatives and funding for cancer research and treatment are driving drug development and accessibility, ensuring that effective ovarian cancer drugs are available in hospital settings. Based on application, the commercial segment dominated with the largest revenue share of 88.0% in 2022. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
  • For instance, in 2020, according to the Commonwealth of Australia, the Australian Government allocated USD 16.2 million toward eight research projects dedicated to addressing ovarian cancer. In Australia or globally, ovarian cancer has consistently maintained the lowest survival rate among all female cancers. On average, 43 out of every 100 women diagnosed with ovarian cancer survived five years after their diagnosis.
  • The online pharmacy segment is expected to grow at the fastest CAGR of 8.1% over the forecast period. The convenience of online pharmacies in facilitating the ordering and delivery of ovarian cancer drugs directly to patients' homes, particularly those with health limitations, is a significant driver of the online pharmacy segment in the ovarian cancer drugs treatment market. This accessibility eliminates barriers to obtaining essential medications, enhancing patient adherence to treatment regimens and expanding the market reach for these drugs.
  • For instance, AdooQ BioScience provides a convenient platform for customers to order ovarian cancer drugs, specifically Rucaparib. On the webpage, customers can access detailed information about the drug, including its name, description, dosage forms, and pricing.
  • North America dominated the industry with a market share of 43.47% in 2022 due to various factors, such as the high incidence of ovarian cancer in North America is a key driver of the region's ovarian cancer drugs market as it results in a significant and ongoing demand for effective treatments, fostering pharmaceutical research, and innovation to cater to the needs of the substantial patient population.
  • For instance, according to the American Cancer Society's 2023 estimates for ovarian cancer in the United States, approximately 19,710 women are expected to be newly diagnosed, while approximately 13,270 women are projected to lose their lives to ovarian cancer. *
  • Asia Pacific is expected to witness the fastest CAGR of 8.0% over the forecast period due to the increased participation in clinical trials in the region not only provides ovarian cancer patients with access to cutting-edge treatments but also fosters drug development by attracting pharmaceutical companies and researchers, thereby advancing the ovarian cancer drugs market in the region. *
  • For instance, according to the Clinical Trials Arena, from 2017 to 2022, Asia Pacific experienced an impressive increase of approximately 10% in clinical trials, surpassing the growth rate observed in other major regions like the U.S. and Europe. This growth in the region significantly outpaced the overall average of 5.3% per year during the same period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapeutic Class
    • 1.1.2. Treatment
    • 1.1.3. End-use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapeutic class outlook
    • 2.2.2. Treatment outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Ovarian Cancer Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Ovarian Cancer Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Ovarian Cancer Drugs: Therapeutic Class Estimates & Trend Analysis

  • 4.1. Ovarian Cancer Drugs Market: Key Takeaways
  • 4.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. PARP Inhibitors
    • 4.3.1. PARP inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Angiogenesis inhibitors
    • 4.4.1. Angiogenesis inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. PD-L1 inhibitors
    • 4.5.1. PD-L1 inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Ovarian Cancer Drugs: End-use Estimates & Trend Analysis

  • 5.1. Ovarian Cancer Drugs Market: Key Takeaways
  • 5.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospital Pharmacy
    • 5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Retail pharmacy
    • 5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Online Pharmacy
    • 5.5.1. Online pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Ovarian Cancer Drugs: Treatment Estimates & Trend Analysis

  • 6.1. Ovarian Cancer Drugs Market: Key Takeaways
  • 6.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Chemotherapy
    • 6.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Radiation Therapy
    • 6.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Hormonal Therapy
    • 6.5.1. Hormonal therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Targeted Therapy & others
    • 6.6.1. Targeted therapy & others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Ovarian Cancer Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Ovarian Cancer Drugs Market by Region: Key Takeaway
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. AbbVie Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Pfizer, Inc.,
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. AstraZeneca,
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. F. Hoffmann-La Roche AG,
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Johnson & Johnson Services, Inc.,
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Boehringer Ingelheim International GmbH,
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Clovis Oncology,
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. ImmunoGen, Inc.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Vivesto AB
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 3 North America ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 4 North America ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 North America ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 7 U.S. ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 U.S. ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 10 Canada ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 11 Canada ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 13 Europe ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Europe ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 15 Europe ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 17 Germany ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 18 Germany ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 UK ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 20 UK ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 UK ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 23 France ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 24 France ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 26 Italy ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Italy ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 29 Spain ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 Spain ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Sweden ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 32 Sweden ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 Sweden ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Norway ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 35 Norway ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Norway ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Denmark ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 38 Denmark ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 39 Denmark ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 44 China ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 45 China ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 China ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Japan ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 48 Japan ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 49 Japan ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 51 India ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 52 India ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Thailand ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 54 Thailand ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Thailand ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 South Korea ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 57 South Korea ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 South Korea ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Latin America ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 60 Latin America ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 61 Latin America ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 63 Brazil ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 64 Brazil ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 65 Brazil ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Mexico ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 67 Mexico ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 68 Mexico ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Argentina ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 70 Argentina ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 71 Argentina ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Middle East and Africa ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 73 Middle East and Africa ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 74 Middle East and Africa ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
  • Table 76 South Africa ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 77 South Africa ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 78 South Africa ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 80 Saudi Arabia ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 UAE ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 83 UAE ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 84 UAE ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 Kuwait ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 86 Kuwait ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 87 Kuwait ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Ovarian cancer drugs: Market outlook
  • Fig. 9 Ovarian cancer drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Ovarian cancer drugs market driver impact
  • Fig. 15 Ovarian cancer drugs market restraint impact
  • Fig. 16 Ovarian cancer drugs market strategic initiatives analysis
  • Fig. 17 Ovarian cancer drugs market: Therapeutic Class movement analysis
  • Fig. 18 Ovarian cancer drugs market: Therapeutic Class outlook and key takeaways
  • Fig. 19 PARP inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Angiogenesis inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 PD-L1 inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Ovarian cancer drugs market: Treatment movement analysis
  • Fig. 23 Ovarian cancer drugs market: Treatment outlook and key takeaways
  • Fig. 24 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Ovarian cancer drugs market: End-use movement analysis
  • Fig. 28 Ovarian cancer drugs market: End-use outlook and key takeaways
  • Fig. 29 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Hormonal therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Targeted therapy & others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Global ovarian cancer drugs market: Regional movement analysis
  • Fig. 34 Global ovarian cancer drugs market: Regional outlook and key takeaways
  • Fig. 35 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)